期刊文献+

多黏菌素类抗生素临床应用研究进展 被引量:2

Research progress of the clinical applications of polymyxins
在线阅读 下载PDF
导出
摘要 随着细菌耐药增强与抗菌新药减少的矛盾不断加剧,多黏菌素类抗生素重又受到临床的重视。虽然其不良反应突出,但却具有明确的抗耐药革兰阴性杆菌活性。本文介绍近5年来有关多黏菌素类抗生素临床应用的研究进展。 More and more attention has been paid to the use of polymyxins in clinic due to the increase in bacterial resistance to antimicrobial agents and the decrease of novel antibacterial agents. Although its adverse reactions are serious, it has demonstrated a definite activity against multidrug-resistant Gram-negative bacteria. This article reviews a recent research progress of polymyxins.
出处 《上海医药》 CAS 2015年第23期14-17,24,共5页 Shanghai Medical & Pharmaceutical Journal
关键词 多黏菌素类抗生素 临床应用 耐药菌 polymyxins clinical application drug-resistant bacteria
作者简介 丁天然,药师。研究方向:抗菌药物的合理应用。E—mail:dingtianran@shaphc.org 通讯作者:张永信,教授。研究方向:抗菌药物的临床应用。E—mail:zhangyongxin1943@tom.com
  • 相关文献

参考文献16

  • 1Wertheim H, Van Nguyen K, Hara GL, et al. Global survey of polymyxin use: a call for international guidelines [J]. J Glob Antimicrob Resist, 2013, 1(3): 131-134.
  • 2Huang J, Tang YQ, Sun JY. Intravenous eolistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections [J]. Scand J Infect Dis, 2010, 42(4): 260-265.
  • 3Lee J, Patel G, Huprikar S, et al. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection [J]. J Clin Microbiol, 2009, 47(5): 1611-1612.
  • 4Fitzpatrick MA, Esterly JS, Postelnick M J, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam [J]. Ann Pharmacother, 2012, 46(7-8): el7.
  • 5Athanassa ZE, Myrianthefs PM, Boutzouka EG, et al. Monotherapy with inhaled colistin for the treatment of patients with ventilator-associated tracheobronchitis due to polymyxin-only-susceptible Gram-negative bacteria [J]. J Hosp Infect, 2011, 78(4): 335-336.
  • 6Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective [J]. Crit Care, 2014, 18(3): 309.
  • 7Elias LS, Konzen D, Krebs JM, et aI. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic [J]. J Antimicrob Chemother, 2010, 65(10): 2231-2237.
  • 8Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinctics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens [J]. Clin Infect Dis, 2013, 57(4): 524-531.
  • 9Zhou YP, Chua NG, Chlebicki MP, et al. Nonattenuated polymyxin B used for the treatment of extreme-drug resistant Acinetobacter baumannii-related infections in patients with preexisting end stage renal failure [J/OL]. Case Rep Infect Dis, 2014, 2014:573279 [2014-11-13]. http://www.ncbi.nlm. nih.gov/pmc/articles/PMC4065743/pdf/CRIID2014-573279. pdf.
  • 10Sandri AM, Landersdorfer CB, Jacob J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis [J]. J Antimicrob Chemother, 2013, 68(3): 674-677.

同被引文献11

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部